NASDAQ:EPZM
Delisted
Epizyme Stock News
$1.47
+0 (+0%)
At Close: Nov 10, 2022
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More
02:03pm, Friday, 27'th Mar 2020
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread
Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound?
03:30pm, Wednesday, 25'th Mar 2020
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound?
03:30pm, Wednesday, 25'th Mar 2020
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound?
12:00am, Wednesday, 25'th Mar 2020Zacks: Brokerages Anticipate Epizyme Inc (NASDAQ:EPZM) Will Announce Quarterly Sales of $2.32 Million
09:06am, Tuesday, 24'th Mar 2020
Brokerages expect Epizyme Inc (NASDAQ:EPZM) to announce $2.32 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Epizyme’s earn
Epizyme Inc (NASDAQ:EPZM) to Post Q1 2021 Earnings of ($0.49) Per Share, Wedbush Forecasts
06:34am, Monday, 23'rd Mar 2020
Epizyme Inc (NASDAQ:EPZM) – Wedbush issued their Q1 2021 earnings per share (EPS) estimates for Epizyme in a research report issued on Wednesday, March 18th. Wedbush analyst D. Nierengarten expects
Citigroup Inc. Lowers Stock Holdings in Epizyme Inc (NASDAQ:EPZM)
10:30am, Saturday, 21'st Mar 2020
Citigroup Inc. reduced its position in Epizyme Inc (NASDAQ:EPZM) by 68.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 27,243 shares of the biopharmaceutical co
Looking At The Investment Case For Epizyme
06:21pm, Friday, 20'th Mar 2020
Today, we take a look at Epizyme, a Tier 4 biotech concern transitioning to Tier 3 status. The company recently received its first FDA approval and has other po
Epizyme hires Kutok as CSO to find new uses for Tazverik
11:36am, Friday, 20'th Mar 2020
Epizyme has appointed Jeffery Kutok as its chief scientific officer. In luring Kutok away from Infinity Pharmaceuticals, Epizyme has gained a scientific leader it thinks will help find new uses for Ta
BRIEF-Epizyme Appoints Jeffery Kutok As Chief Scientific Officer
10:31am, Friday, 20'th Mar 2020
Epizyme Inc:
Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
10:30am, Friday, 20'th Mar 2020
Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
3 Cancer Treatment Stocks to Buy Right Now
10:45am, Thursday, 19'th Mar 2020
Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.
A Director at Epizyme is Exercising Options
07:54am, Thursday, 19'th Mar 2020
Yesterday it was reported that a Director at Epizyme (EPZM – Research Report), Andrew Allen, exercised options to buy 12,500
Goldman likes McKesson in premarket analyst action
11:53am, Wednesday, 18'th Mar 2020
Osmotica Pharmaceuticals (NASDAQ:OSMT) initiated with Buy rating and $8 (74% upside) price target at SunTrust.Epizyme (NASDAQ:EPZM) added to Best Ideas List at Wedbush with a $30 (68% upside) price ta
Epizyme Inc (NASDAQ:EPZM) Shares Sold by ProShare Advisors LLC
11:40am, Wednesday, 18'th Mar 2020
ProShare Advisors LLC reduced its stake in Epizyme Inc (NASDAQ:EPZM) by 5.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 31,663 shares of th
